<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Whitlock, Richard</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Methylprednisolone Not Beneficial in High-Risk Cardiac Surgery Patients (SIRS)</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">23-24</style></pages><abstract><style  face="normal" font="default" size="100%">This article discusses the findings of the Steroids in Cardiac Surgery Trial [SIRS Trial; NCT00427388]. Inflammation triggered by cardiopulmonary bypass can be diminished using prophylactic steroids, which may produce clinical benefits. The SIRS trial assessed the hypothesis of whether methylprednisolone would reduce perioperative adverse events in high-risk patients undergoing cardiac surgery involving cardiopulmonary bypass.</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>